Home > News > Elan and EntreMed Execute License Agreement
January 13th, 2006
Elan and EntreMed Execute License Agreement
Abstract:
Elan Corporation, plc (NYSE: ELN) and EntreMed, Inc. (Nasdaq: ENMD) today announced that they have entered into a License Agreement in which EntreMed has been granted rights to utilize Elan's proprietary NanoCrystal Technology to develop the oncology product candidate, PanzemŽ NCD (2ME2 or 2-methoxyestradiol).
Source:
Elan Corporation
Related News Press |
Nanomedicine
High-tech 'paint' could spare patients repeated surgeries March 8th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Materials/Metamaterials/Magnetoresistance
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||